CEO Stéphane Bancel was paid $19,932,217 in fiscal year 2025, ↑ up 0.3% from fiscal year 2024, the 53rd percentile of its disclosed peer group (SEC filing 0001308179-26-000081 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$19,932,217 ↑ Stéphane Bancel total, FY2025 | 53rd CEO pay percentile vs peers | 89:1 CEO-to-median pay ratio | 65.11% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
MRNA's next annual pay disclosure, estimated March 21, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Stéphane Bancel | $1,677,739 | $0 | $6,897,455 | $6,897,425 | $4,302,360 | $0 | $157,238 | $19,932,217 |
| Chief Executive Officer | ||||||||
| Stephen Hoge | 1,260,000 | 0 | 9,196,606 | 4,598,277 | 2,983,500 | 0 | 15,750 | 18,054,133 |
| President | ||||||||
| James Mock | 852,192 | 0 | 2,452,404 | 1,226,205 | 1,311,210 | 0 | 15,750 | 5,857,761 |
| Chief Financial Officer | ||||||||
| Shannon Klinger | 852,192 | 0 | 2,145,838 | 1,072,924 | 1,311,210 | 0 | 15,750 | 5,397,914 |
| Chief Legal Officer and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Stéphane Bancel | $19,932,217 | $19,876,180 | $17,068,514 | ↑ +56,037 |
| Stephen Hoge | 18,054,133 | 9,181,478 | 7,339,166 | ↑ +8,872,655 |
| James Mock | 5,857,761 | 17,212,582 | 4,317,185 | ↓ −11,354,821 |
| Shannon Klinger | 5,397,914 | 17,368,701 | 4,312,496 | ↓ −11,970,787 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Moderna, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper MRNA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Moderna, Inc. Peer Teardown Report
$19,932,217 Stéphane Bancel total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 16, 2026 · Source: 0001308179-26-000081 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for MRNA
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order MRNA
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name MRNA as a peer is temporarily unavailable — recheck shortly.
Get the Moderna, Inc. Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| James Mock | CFO | $5,857,761 |
| Shannon Klinger | General Counsel | $5,397,914 |
| Stéphane Bancel | CEO | $19,932,217 |
| Stephen Hoge | President | $18,054,133 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Abbas Hussain | Independent Director | $543,290 |
| David Rubenstein | Independent Director | $543,272 |
| Elizabeth Nabel, M.D | Independent Director | $543,290 |
| Elizabeth Tallett | Independent Director | $563,277 |
| François Nader, M.D | Independent Director | $583,267 |
| Noubar Afeyan, Ph.D | Chair of the Board | $658,423 |
| Paul Sagan | Independent Director | $543,281 |
| Sandra Horning, M.D | Independent Director | $563,290 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-04-02 | — | 1,453 | — | — | 1 insider, 1 accrual row | ||
| James Mock | Chief Financial Officer | 2026-04-02 | A | 1,453 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-04-02 | D | 703 | 50 | 35,171 | Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | D | 12,174 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | A | 8,116 | — | — | Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | A | 4,058 | — | — | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | D | 4,058 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | A | 12,174 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | D | 8,116 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-05-01 | D | 5,682 | 47 | 264,952 | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 6,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-06 | A | 12,908 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 4,185 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 53,336 | 48 | 2,581,462 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | A | 9,263 | 19 | 177,386 | Common, indirect | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 47 | 433,879 | Common, indirect | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-27 | — | 2,983 | — | — | 3 insiders, 3 accrual rows | ||
| Stephen Hoge | President | 2026-05-27 | D | 695 | 47 | 32,686 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | A | 1,437 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-28 | — | 1,266 | — | — | 3 insiders, 3 accrual rows | ||
| Stephen Hoge | President | 2026-05-28 | D | 295 | 48 | 14,045 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-28 | A | 610 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-28 | A | 328 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-28 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-28 | A | 328 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-28 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 9,282 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 4,488 | 47 | 211,789 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | A | 9,282 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 2,165 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 1,047 | 47 | 49,408 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 2,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 1,197 | 47 | 56,486 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | A | 2,475 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | A | 2,165 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | A | 3,471 | 31 | 107,462 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 50 | 173,550 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-05 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-05 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-05 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 53,336 | 51 | 2,739,870 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-02 | — | 1,452 | — | — | 1 insider, 1 accrual row | ||
| James Mock | Chief Financial Officer | 2026-07-02 | D | 703 | 73 | 50,968 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | A | 1,452 | — | — | Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 18,658 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 38,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-08 | — | 1,618 | — | — | 1 insider, 1 accrual row | ||
| Michael R. McDonnell | Director | 2026-07-08 | A | 5,733 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 7,415 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 53,336 | 68 | 3,605,514 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 370,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 147,473 | 56 | 8,289,457 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 128,393 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 187,044 | 59 | 10,996,317 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 39,891 | 58 | 2,318,465 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 124,838 | 57 | 7,110,772 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | A | 499,246 | 19 | 9,560,561 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-06 | D | 64,928 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-06 | D | 187,541 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-06 | A | 252,469 | 19 | 4,834,781 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-27 | D | 375 | 150 | 56,123 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-27 | — | 2,985 | — | — | 3 insiders, 3 accrual rows | ||
| Stephen Hoge | President | 2026-08-27 | D | 695 | 150 | 104,014 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-27 | A | 1,437 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-27 | A | 774 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-27 | D | 375 | 150 | 56,123 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-27 | A | 774 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-28 | D | 160 | 143 | 22,843 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-28 | A | 329 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-28 | A | 611 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-28 | — | 1,269 | — | — | 3 insiders, 3 accrual rows | ||
| Stephen Hoge | President | 2026-08-28 | D | 296 | 143 | 42,260 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-28 | D | 160 | 143 | 22,843 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-28 | A | 329 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 1,048 | 140 | 147,076 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | A | 2,166 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-01 | D | 4,489 | 140 | 629,986 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-01 | D | 9,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-01 | D | 2,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-01 | A | 2,475 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 2,166 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | A | 3,471 | 31 | 107,462 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-01 | D | 1,197 | 140 | 167,987 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-01 | A | 9,283 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 3,471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 3,471 | 140 | 485,766 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-04 | D | 11,797 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-04 | D | 11,797 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-04 | A | 11,797 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-04 | D | 5,704 | 149 | 849,154 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-04 | D | 5,704 | 149 | 849,154 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-04 | A | 11,797 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | D | 19,836 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | D | 15,000 | 134 | 2,017,350 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | D | 19,836 | 134 | 2,667,744 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | A | 19,836 | 31 | 614,123 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-14 | D | 76,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-14 | A | 76,453 | 12 | 933,491 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-14 | D | 40,294 | 144 | 5,807,574 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-15 | D | 76,452 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-15 | D | 40,281 | 146 | 5,883,846 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-15 | A | 76,452 | 12 | 933,479 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-05 | — | 1,454 | — | — | 1 insider, 1 accrual row | ||
| James Mock | Chief Financial Officer | 2026-10-05 | D | 704 | 190 | 133,767 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-10-05 | A | 1,454 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | D | 76,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | D | 450 | 214 | 96,368 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | D | 38,774 | 213 | 8,277,086 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | A | 76,453 | 12 | 933,491 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-15 | D | 76,452 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-15 | D | 39,145 | 221 | 8,640,084 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-15 | A | 76,452 | 12 | 933,479 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Mock | Chief Financial Officer | 2026-04-02 | D | 1,453 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-04-02 | A | 1,453 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-04-02 | D | 703 | 50 | 35,171 | Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | D | 12,174 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | A | 8,116 | — | — | Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | A | 16,233 | — | — | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | A | 4,058 | — | — | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-04-30 | D | 4,058 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-04-30 | A | 12,174 | — | — | Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-04-30 | D | 8,116 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-04-30 | D | 16,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-05-01 | D | 5,682 | 47 | 264,952 | Common | Form 4 ↗ |
| Elizabeth Tallett | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 6,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-06 | A | 12,908 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. Nabel | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abbas Hussain | Director | 2026-05-06 | A | 8,371 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 2,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Rubenstein | Director | 2026-05-06 | A | 9,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francois Nader | Director | 2026-05-06 | A | 4,185 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 53,336 | 48 | 2,581,462 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | A | 9,263 | 19 | 177,386 | Common, indirect | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noubar Afeyan | Director | 2026-05-21 | D | 9,263 | 47 | 433,879 | Common, indirect | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 773 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 1,437 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | D | 695 | 47 | 32,686 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-27 | A | 773 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-27 | A | 1,437 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 773 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-27 | D | 374 | 47 | 17,589 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-28 | D | 328 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-28 | D | 610 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-28 | D | 295 | 48 | 14,045 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-05-28 | A | 610 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-28 | A | 328 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-28 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-05-28 | A | 328 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-28 | D | 328 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-05-28 | D | 159 | 48 | 7,570 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 9,282 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | D | 4,488 | 47 | 211,789 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-01 | A | 9,282 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 2,165 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | D | 1,047 | 47 | 49,408 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 2,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | D | 1,197 | 47 | 56,486 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-01 | A | 2,475 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-01 | A | 2,165 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | A | 3,471 | 31 | 107,462 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-04 | D | 3,471 | 50 | 173,550 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-05 | D | 11,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-06-05 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-05 | D | 5,705 | 52 | 294,321 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-06-05 | A | 11,798 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 53,336 | 51 | 2,739,870 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-06-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | D | 1,452 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | D | 703 | 73 | 50,968 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-07-02 | A | 1,452 | — | — | Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 18,658 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Soria Ester Banque | Chief Commercial Officer | 2026-07-05 | A | 38,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 1,618 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 5,733 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. McDonnell | Director | 2026-07-08 | A | 7,415 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 16,110 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 16,110 | 19 | 308,507 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 37,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | D | 53,336 | 68 | 3,605,514 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-07-15 | A | 37,226 | 19 | 712,878 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 370,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 147,473 | 56 | 8,289,457 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 128,393 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 187,044 | 59 | 10,996,317 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 39,891 | 58 | 2,318,465 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | D | 124,838 | 57 | 7,110,772 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-05 | A | 499,246 | 19 | 9,560,561 | Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-06 | D | 64,928 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-06 | D | 187,541 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stéphane Bancel | Director | 2026-08-06 | A | 252,469 | 19 | 4,834,781 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-27 | D | 375 | 150 | 56,123 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-27 | D | 1,437 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-27 | D | 695 | 150 | 104,014 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-27 | A | 1,437 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-27 | A | 774 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-27 | D | 774 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-27 | D | 375 | 150 | 56,123 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-27 | A | 774 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-27 | D | 774 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-28 | D | 160 | 143 | 22,843 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-28 | A | 329 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-28 | A | 611 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-28 | D | 611 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-08-28 | D | 296 | 143 | 42,260 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-08-28 | D | 329 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-28 | D | 329 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-28 | D | 160 | 143 | 22,843 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-08-28 | A | 329 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 1,048 | 140 | 147,076 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | A | 2,166 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-01 | D | 4,489 | 140 | 629,986 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-01 | D | 9,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-01 | D | 2,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-01 | A | 2,475 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 2,166 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | A | 3,471 | 31 | 107,462 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-01 | D | 1,197 | 140 | 167,987 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-01 | A | 9,283 | — | — | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 3,471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-01 | D | 3,471 | 140 | 485,766 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-04 | D | 11,797 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-04 | D | 11,797 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-04 | A | 11,797 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-04 | D | 5,704 | 149 | 849,154 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-04 | D | 5,704 | 149 | 849,154 | Common | Form 4 ↗ |
| Shannon Klinger | Chief Legal Officer | 2026-09-04 | A | 11,797 | — | — | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | D | 19,836 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | D | 15,000 | 134 | 2,017,350 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | D | 19,836 | 134 | 2,667,744 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-09-10 | A | 19,836 | 31 | 614,123 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-14 | D | 76,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-14 | A | 76,453 | 12 | 933,491 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-14 | D | 40,294 | 144 | 5,807,574 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-15 | D | 76,452 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-15 | D | 40,281 | 146 | 5,883,846 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-09-15 | A | 76,452 | 12 | 933,479 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-10-05 | D | 1,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-10-05 | D | 704 | 190 | 133,767 | Common | Form 4 ↗ |
| James Mock | Chief Financial Officer | 2026-10-05 | A | 1,454 | — | — | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | D | 76,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | D | 450 | 214 | 96,368 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | D | 38,774 | 213 | 8,277,086 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-14 | A | 76,453 | 12 | 933,491 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-15 | D | 76,452 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-15 | D | 39,145 | 221 | 8,640,084 | Common | Form 4 ↗ |
| Stephen Hoge | President | 2026-10-15 | A | 76,452 | 12 | 933,479 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Stephen Hoge | RSU | 2025-03-01 | — | — | 148,524 | — | $4,598,303 |
| James Mock | PSU | 2025-03-01 | 19,803 | 39,606 | — | 79,212 | 1,226,202 |
| Shannon Klinger | RSU | 2025-03-01 | — | — | 34,655 | — | 1,072,919 |
| Stéphane Bancel | PSU | 2025-03-01 | 111,393 | 222,786 | — | 445,572 | 6,897,455 |
| Shannon Klinger | PSU | 2025-03-01 | 17,327 | 34,655 | — | 69,310 | 1,072,919 |
| James Mock | RSU | 2025-03-01 | — | — | 39,606 | — | 1,226,202 |
| Stephen Hoge | PSU | 2025-03-01 | 74,262 | 148,524 | — | 297,048 | 4,598,303 |
| Stephen Hoge | PSU | 2025-03-01 | — | — | — | — | 4,598,277 |
| Stéphane Bancel | PSU | 2025-03-01 | — | — | — | — | 6,897,425 |
| Shannon Klinger | PSU | 2025-03-01 | — | — | — | — | 1,072,924 |
| James Mock | PSU | 2025-03-01 | — | — | — | — | 1,226,205 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Stephen Hoge | $4,598,303 | $9,196,580 | $0 | 66.7% |
| James Mock | 1,226,202 | 2,452,407 | 0 | 66.7% |
| Shannon Klinger | 1,072,919 | 2,145,843 | 0 | 66.7% |
| Stéphane Bancel | 0 | 13,794,880 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| James Mock | RSU | 5,811 | — | $171,366 |
| Shannon Klinger | Option | 944 | 149.52 | — |
| Stephen Hoge | Option | 24,691 | 96.2 | — |
| Stephen Hoge | Option | 11,631 | 138.81 | — |
| Stéphane Bancel | Option | 9,148 | 149.52 | — |
| Stéphane Bancel | Option | 357,065 | 30.96 | — |
| Stephen Hoge | RSU | 3,053 | — | 90,033 |
| Shannon Klinger | Option | 55,543 | 30.96 | — |
| Shannon Klinger | RSU | 141,571 | — | 4,174,929 |
| James Mock | RSU | 6,963 | — | 205,339 |
| Shannon Klinger | RSU | 12,377 | — | 364,998 |
| James Mock | Option | 10,969 | 125.62 | — |
| Shannon Klinger | Option | 13,296 | 96.2 | — |
| Shannon Klinger | Option | 60,216 | 96.2 | — |
| James Mock | Option | 6,263 | 138.81 | — |
| Shannon Klinger | RSU | 6,963 | — | 205,339 |
| Shannon Klinger | Option | 6,263 | 138.81 | — |
| James Mock | RSU | 5,260 | — | 155,117 |
| Shannon Klinger | RSU | 5,260 | — | 155,117 |
| Shannon Klinger | RSU | 1,644 | — | 48,482 |
| Stephen Hoge | RSU | 652 | — | 19,227 |
| Stéphane Bancel | Option | 40,260 | 138.81 | — |
| Stéphane Bancel | Option | 85,469 | 96.2 | — |
| James Mock | Option | 13,296 | 96.2 | — |
| Stephen Hoge | Option | 2,644 | 149.52 | — |
| Stéphane Bancel | RSU | 222,786 | — | 6,569,959 |
| James Mock | RSU | 141,571 | — | 4,174,929 |
| Stephen Hoge | Option | 238,043 | 30.96 | — |
| Stéphane Bancel | RSU | 79,571 | — | 2,346,549 |
| James Mock | Option | 63,478 | 30.96 | — |
| Stephen Hoge | RSU | 12,931 | — | 381,335 |
| Shannon Klinger | RSU | 233 | — | 6,871 |
| James Mock | Option | 60,216 | 96.2 | — |
| James Mock | RSU | 1,644 | — | 48,482 |
| James Mock | RSU | 12,377 | — | 364,998 |
| James Mock | RSU | 39,606 | — | 1,167,981 |
| Stephen Hoge | RSU | 148,524 | — | 4,379,973 |
| Shannon Klinger | RSU | 34,655 | — | 1,021,976 |
| Stephen Hoge | RSU | 22,987 | — | 677,887 |
| Stéphane Bancel | RSU | 22,543 | — | 664,793 |
| Stephen Hoge | RSU | 9,768 | — | 288,058 |
Our executive compensation program is guided by our overarching philosophy of paying for demonstrable performance and impact.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-06 | 169,401,841 | 90,761,924 | 440,050 | 65.11% | Passed |
| 2024 | 2024-05-06 | 248,175,284 | 25,923,518 | 488,279 | 90.54% | Passed |
| 2023 | 2023-05-03 | 254,146,335 | 34,946,612 | 1,618,048 | 87.91% | Passed |
| 2022 | 2022-04-28 | 277,970,064 | 20,992,879 | 442,036 | 92.98% | Passed |
| 2021 | 2021-04-28 | 222,266,802 | 16,973,022 | 2,483,790 | 91.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-06 | 65.11%a |
| 2024 | 2024-05-06 | 90.54%b |
| 2023 | 2023-05-03 | 87.91%c |
a. Approved under the standard stated in the filing — “2, the abstention will have no effect on the results of this vote.”.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “2, the abstention will have no effect on the results of this vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 89 : 1 |
|---|---|
| CEO total compensation | $19,932,217 |
| Median employee compensation | $225,053 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Noubar Afeyan, Ph.DNot independent · Board Chair | $130,000 | — | $463,281 | $0 | $65,142 | $658,423 |
| François Nader, M.DIndependent · Compensation and Talent (Chair) · Nominating and Corporate Governance (Chair) | 120,000 | 347,446 | 115,821 | 0 | — | 583,267 |
| Sandra Horning, M.DIndependent · Product and Technology (Chair) · Nominating and Corporate Governance | 100,000 | 463,290 | — | 0 | — | 563,290 |
| Elizabeth TallettIndependent · Audit (Chair) · Compensation and Talent | 100,000 | 115,816 | 347,461 | 0 | — | 563,277 |
| Abbas HussainIndependent · Audit · Product and Technology | 80,000 | 463,290 | — | 0 | — | 543,290 |
| Elizabeth Nabel, M.DIndependent · Compensation and Talent · Product and Technology | 80,000 | 463,290 | — | 0 | — | 543,290 |
| Paul SaganIndependent · Audit · Nominating and Corporate Governance · Not standing for re-election | 80,000 | — | 463,281 | 0 | — | 543,281 |
| David RubensteinIndependent · Audit | 80,000 | 231,631 | 231,641 | 0 | — | 543,272 |
| Stéphane BancelEmployee director · Executive (Chair) | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $80,000 |
|---|---|
| Annual equity retainer | $425,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | 6x annual cash retainer ($480,000) |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $770,000 |
| Equity awards (grant-date value) | $2,084,763 |
| All other compensation | $65,142 |
| Total cost of the board | $2,919,905 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Moderna, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Moderna, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Biogen | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 4 | PTC Therapeutics | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 5 | BioMarin Pharmaceutical | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Bristol-Myers Squibb | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 7 | Vertex Pharmaceuticals | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 8 | Merck | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 9 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 10 | Jazz Pharmaceuticals | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 11 | United Therapeutics | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 12 | BeOne Medicines | 2025 | John Oyler | 1,133,000 | 11,249,615 | 3,749,967 | 1,676,840 | 17,943,521 |
| 13 | Alnylam Pharmaceuticals | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 14 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 15 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 16 | Ultragenyx Pharmaceutical | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 17 | Sarepta Therapeutics | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 18 | Regeneron Pharmaceuticals | 2025 | Leonard Schleifer | 1,979,922 | 0 | 0 | 3,682,655 | 7,280,549 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Alnylam Pharmaceuticals | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| BeOne Medicines | 148% | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Biogen | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Bristol-Myers Squibb | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Exelixis | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Merck | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Neurocrine Biosciences | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Regeneron Pharmaceuticals | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| Sarepta Therapeutics | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Ultragenyx Pharmaceutical | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics | 221% | PSO 50 · PSU 50 | No | Aon |
| Vertex Pharmaceuticals | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Stéphane Bancel | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 2 | Section 01, Stephen Hoge | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 18,054,133. Filing ↗machine: r8 · c45 · span 1153380–1153390 |
| 3 | Section 01, James Mock | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 5,857,761. Filing ↗machine: r5 · c45 · span 1143143–1143152 |
| 4 | Section 01, Shannon Klinger | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “2025 Summary Compensation Table”. As printed: 5,397,914. Filing ↗machine: r11 · c45 · span 1164089–1164098 |
| 5 | Section 03, Stephen Hoge RSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1216698–1216707 |
| 6 | Section 03, James Mock PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1212380–1212389 |
| 7 | Section 03, Shannon Klinger RSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1223577–1223586 |
| 8 | Section 03, Stéphane Bancel PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1205682–1205691 |
| 9 | Section 03, Shannon Klinger PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1226492–1226501 |
| 10 | Section 03, James Mock RSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1209990–1209999 |
| 11 | Section 03, Stephen Hoge PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1219090–1219099 |
| 12 | Section 03, Stephen Hoge PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1214887–1214896 |
| 13 | Section 03, Stéphane Bancel PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1203288–1203297 |
| 14 | Section 03, Shannon Klinger PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1221767–1221776 |
| 15 | Section 03, James Mock PSU | DEF 14A | 1900-01-01 | 0001308179-26-000081 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1208180–1208189 |
| 16 | Section 07, pay ratio | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “CEO Pay Ratio”. As printed: 89 : 1. Filing ↗machine: span 1528497–1528504 |
| 17 | Section 08, Noubar Afeyan, Ph.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 658,423. Filing ↗machine: t95 · r2 · c16 · span 617241–617376 |
| 18 | Section 08, François Nader, M.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 583,267. Filing ↗machine: t95 · r6 · c13 · span 627225–627546 |
| 19 | Section 08, Sandra Horning, M.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 563,290. Filing ↗machine: t95 · r3 · c13 · span 619599–619920 |
| 20 | Section 08, Elizabeth Tallett | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 563,277. Filing ↗machine: t95 · r9 · c13 · span 635256–635647 |
| 21 | Section 08, Abbas Hussain | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,290. Filing ↗machine: t95 · r4 · c13 · span 622134–622455 |
| 22 | Section 08, Elizabeth Nabel, M.D | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,290. Filing ↗machine: t95 · r5 · c13 · span 624677–624998 |
| 23 | Section 08, Paul Sagan | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,281. Filing ↗machine: t95 · r8 · c13 · span 632295–632616 |
| 24 | Section 08, David Rubenstein | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 543,272. Filing ↗machine: t95 · r7 · c13 · span 629763–630084 |
| 25 | Section 08, Stéphane Bancel | DEF 14A | 2026-03-16 | 0001308179-26-000081 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 02, James Mock 2026-04-02 | Form 4 | 2026-04-06 | 0001682852-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, James Mock 2026-04-02 | Form 4 | 2026-04-06 | 0001682852-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, James Mock 2026-04-02 | Form 4 | 2026-04-06 | 0001682852-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Francois Nader 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Elizabeth G. Nabel 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Elizabeth G. Nabel 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Abbas Hussain 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, David Rubenstein 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Sandra Horning 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Elizabeth Tallett 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Elizabeth Tallett 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Francois Nader 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Abbas Hussain 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, David Rubenstein 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Sandra Horning 2026-04-30 | Form 4 | 2026-05-04 | 0001682852-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Abbas Hussain 2026-05-01 | Form 4 | 2026-05-04 | 0001682852-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Elizabeth Tallett 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Sandra Horning 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Sandra Horning 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Francois Nader 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Noubar Afeyan 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Elizabeth G. Nabel 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Abbas Hussain 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, David Rubenstein 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, David Rubenstein 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Francois Nader 2026-05-06 | Form 4 | 2026-05-08 | 0001682852-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Stephen Hoge 2026-05-15 | Form 4 | 2026-05-18 | 0001682852-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Noubar Afeyan 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237309 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Noubar Afeyan 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237309 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Noubar Afeyan 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237309 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, James Mock 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Stephen Hoge 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Shannon Klinger 2026-05-27 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, James Mock 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Stephen Hoge 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Stephen Hoge 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Stephen Hoge 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Shannon Klinger 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, James Mock 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, James Mock 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Shannon Klinger 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Shannon Klinger 2026-05-28 | Form 4 | 2026-05-29 | 0001682852-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Stephen Hoge 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Stephen Hoge 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Stephen Hoge 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Shannon Klinger 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Shannon Klinger 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, James Mock 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, James Mock 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, James Mock 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Shannon Klinger 2026-06-01 | Form 4 | 2026-06-03 | 0001682852-26-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Shannon Klinger 2026-06-04 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, James Mock 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Shannon Klinger 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, James Mock 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, James Mock 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Shannon Klinger 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Shannon Klinger 2026-06-05 | Form 4 | 2026-06-08 | 0001682852-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Stephen Hoge 2026-06-15 | Form 4 | 2026-06-17 | 0001682852-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, James Mock 2026-07-02 | Form 4 | 2026-07-06 | 0001682852-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, James Mock 2026-07-02 | Form 4 | 2026-07-06 | 0001682852-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, James Mock 2026-07-02 | Form 4 | 2026-07-06 | 0001682852-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Soria Ester Banque 2026-07-05 | Form 4 | 2026-07-07 | 0001682852-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Soria Ester Banque 2026-07-05 | Form 4 | 2026-07-07 | 0001682852-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Michael R. McDonnell 2026-07-08 | Form 4 | 2026-07-10 | 0001682852-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Michael R. McDonnell 2026-07-08 | Form 4 | 2026-07-10 | 0001682852-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Michael R. McDonnell 2026-07-08 | Form 4 | 2026-07-10 | 0001682852-26-000139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Stephen Hoge 2026-07-15 | Form 4 | 2026-07-16 | 0001682852-26-000141 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Stéphane Bancel 2026-08-05 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Stéphane Bancel 2026-08-05 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Stéphane Bancel 2026-08-05 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Stéphane Bancel 2026-08-05 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Stéphane Bancel 2026-08-05 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Stéphane Bancel 2026-08-05 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Stéphane Bancel 2026-08-05 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Stéphane Bancel 2026-08-06 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Stéphane Bancel 2026-08-06 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Stéphane Bancel 2026-08-06 | Form 4 | 2026-08-07 | 0001682852-26-000153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Shannon Klinger 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Stephen Hoge 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Stephen Hoge 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Stephen Hoge 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Shannon Klinger 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, James Mock 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, James Mock 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, James Mock 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Shannon Klinger 2026-08-27 | Form 4 | 2026-08-31 | 0001682852-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Shannon Klinger 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Shannon Klinger 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Stephen Hoge 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Stephen Hoge 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Stephen Hoge 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Shannon Klinger 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, James Mock 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, James Mock 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, James Mock 2026-08-28 | Form 4 | 2026-08-31 | 0001682852-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Shannon Klinger 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Shannon Klinger 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Stephen Hoge 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Stephen Hoge 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, James Mock 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, James Mock 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Shannon Klinger 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Shannon Klinger 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, James Mock 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Stephen Hoge 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Shannon Klinger 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Shannon Klinger 2026-09-01 | Form 4 | 2026-09-03 | 0001682852-26-000167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Shannon Klinger 2026-09-04 | Form 4 | 2026-09-08 | 0001682852-26-000169 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, James Mock 2026-09-04 | Form 4 | 2026-09-08 | 0001682852-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, James Mock 2026-09-04 | Form 4 | 2026-09-08 | 0001682852-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, James Mock 2026-09-04 | Form 4 | 2026-09-08 | 0001682852-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Shannon Klinger 2026-09-04 | Form 4 | 2026-09-08 | 0001682852-26-000169 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Shannon Klinger 2026-09-04 | Form 4 | 2026-09-08 | 0001682852-26-000169 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, James Mock 2026-09-10 | Form 4 | 2026-09-14 | 0001682852-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, James Mock 2026-09-10 | Form 4 | 2026-09-14 | 0001682852-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, James Mock 2026-09-10 | Form 4 | 2026-09-14 | 0001682852-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, James Mock 2026-09-10 | Form 4 | 2026-09-14 | 0001682852-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Stephen Hoge 2026-09-14 | Form 4 | 2026-09-16 | 0001682852-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Stephen Hoge 2026-09-14 | Form 4 | 2026-09-16 | 0001682852-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Stephen Hoge 2026-09-14 | Form 4 | 2026-09-16 | 0001682852-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Stephen Hoge 2026-09-15 | Form 4 | 2026-09-16 | 0001682852-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Stephen Hoge 2026-09-15 | Form 4 | 2026-09-16 | 0001682852-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Stephen Hoge 2026-09-15 | Form 4 | 2026-09-16 | 0001682852-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, James Mock 2026-10-05 | Form 4 | 2026-10-07 | 0001682852-26-000185 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, James Mock 2026-10-05 | Form 4 | 2026-10-07 | 0001682852-26-000185 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, James Mock 2026-10-05 | Form 4 | 2026-10-07 | 0001682852-26-000185 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Stephen Hoge 2026-10-14 | Form 4 | 2026-10-16 | 0001682852-26-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Stephen Hoge 2026-10-14 | Form 4 | 2026-10-16 | 0001682852-26-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Stephen Hoge 2026-10-14 | Form 4 | 2026-10-16 | 0001682852-26-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Stephen Hoge 2026-10-14 | Form 4 | 2026-10-16 | 0001682852-26-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Stephen Hoge 2026-10-15 | Form 4 | 2026-10-16 | 0001682852-26-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Stephen Hoge 2026-10-15 | Form 4 | 2026-10-16 | 0001682852-26-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Stephen Hoge 2026-10-15 | Form 4 | 2026-10-16 | 0001682852-26-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 06, 2026 vote | Form 8-K | 2026-05-11 | 0001682852-26-000101 | Item 5.07 · say-on-pay result. As reported: 65.11% (votes for as printed: 169,401,841). Filing ↗ |
| 181 | Section 06, 2024 vote | Form 8-K | 2024-05-09 | 0001682852-24-000031 | Item 5.07 · say-on-pay result. As reported: 90.54% (votes for as printed: 248,175,284). Filing ↗ |
| 182 | Section 06, 2023 vote | Form 8-K | 2023-05-05 | 0001193125-23-137079 | Item 5.07 · say-on-pay result. As reported: 87.91% (votes for as printed: 254,146,335). Filing ↗ |
| 183 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 184 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 185 | Section 09b board cost (computed) | Computed | — | — | Cash 770,000 + equity 2,084,763 + all other 65,142 = 2,919,905, summed across the director compensation table rows.machine: formula: Σ = 2,919,905 |
| 186 | Exelixis, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 187 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 188 | Biogen, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen's own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 189 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗ |
| 190 | BioMarin Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical's own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 191 | Bristol-Myers Squibb, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000014272-26-000006 | CEO total compensation as printed in Bristol-Myers Squibb's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170 |
| 192 | Vertex Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 193 | Merck, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-147704 | CEO total compensation as printed in Merck's own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022 |
| 194 | Moderna, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 195 | Jazz Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 196 | United Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 197 | BeOne Medicines, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-049655 | CEO total compensation as printed in BeOne Medicines's own proxy. As printed: 17,943,521. Filing ↗machine: t180 · r2 · c22 · span 1909011–1909021 |
| 198 | Alnylam Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals's own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 199 | Neurocrine Biosciences, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 200 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗ |
| 201 | Ultragenyx Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 202 | Sarepta Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 203 | Regeneron Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001308179-26-000340 | CEO total compensation as printed in Regeneron Pharmaceuticals's own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989 |
| 204 | Section 10a, Bristol-Myers Squibb reciprocity | DEF 14A | — | 0000014272-26-000006 | Bristol-Myers Squibb's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 205 | Section 10a, United Therapeutics reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 206 | Section 10a, Jazz Pharmaceuticals reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 207 | Section 10a, Sarepta Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 208 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 209 | Section 10a, Ultragenyx Pharmaceutical reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 210 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 211 | Section 10a, BeOne Medicines reciprocity | DEF 14A | — | 0001104659-26-049655 | BeOne Medicines names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 212 | Section 10a, Exelixis reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 213 | Section 10a, Alnylam Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 214 | Section 10a, Merck reciprocity | DEF 14A | — | 0001193125-26-147704 | Merck's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 215 | Section 10a, BioMarin Pharmaceutical reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 216 | Section 10a, Neurocrine Biosciences reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 217 | Section 10a, Regeneron Pharmaceuticals reciprocity | DEF 14A | — | 0001308179-26-000340 | Regeneron Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Moderna, Inc.. Filing ↗ |
| 218 | Section 10a, Vertex Pharmaceuticals reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals names Moderna, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Moderna, Inc. Executive Compensation Report
$1,500